Scintimammography and Gamma Imaging of the Breast and Axilla
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 5.021 alerts
Get alerted when Policy MP 5.021 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage stance for scintimammography, BSGI, MBI, and radiolabeled lymphoscintigraphy/hand-held gamma detection related to breast and axillary evaluation for members of Capital BlueCross products to which the policy applies.
No material clinical or coverage changes in this revision.
Coverage Criteria
Scintimammography / BSGI / MBI - Investigational
Coverage stance summarized
Insufficient evidence of health outcome benefit
Lymphoscintigraphy / Hand-held gamma detection - Medically necessary
Coverage stance for sentinel node localization
Supported by randomized trials and systematic reviews showing similar long-term outcomes to axillary dissection with lower morbidity and high SLN identification success
Scintimammography/BSGI/MBI as adjunct to mammography
Diagnostic adjunctive use
Benefits must be weighed against additional radiation exposure
Indeterminate or suspicious lesions
Evaluation of indeterminate or suspicious lesions
Biopsy remains the criterion standard; evidence insufficient to improve net health outcome
Residual tumor detection after neoadjuvant therapy
Detection of residual tumor after neoadjuvant therapy
Evidence insufficient to demonstrate improved net health outcome
Surgical planning
Surgical planning for breast-conserving therapy
Evidence insufficient to improve net health outcome
Axilla: metastasis detection and SLN localization
Axillary metastasis detection and sentinel lymph node localization
Evidence insufficient to improve net health outcome for replacing standard axillary staging
Evidence sufficient to determine improvement in net health outcome for SLN localization
Diagnosis-based coverage
Covered when medically necessary for the following malignant breast neoplasm diagnoses:
Coverage for scintimammography or gamma imaging of the breast and axilla is tied to the listed C50.* diagnosis codes
The policy follows product labeling and evidence-based guidance: Tc-99m sestamibi is the primary radiopharmaceutical used with BSGI/MBI and, per its label, is indicated as a second-line diagnostic agent after mammography but is not indicated for breast cancer screening, not to confirm the presence or absence of malignancy, and is not an alternative to biopsy. The policy therefore treats scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) as investigational in all applications because current evidence is insufficient to demonstrate net health outcome benefit when used broadly or as a substitute for standard diagnostic procedures.
When considered as an adjunct to mammography (for example in women with dense breasts or elevated risk), studies have reported increased sensitivity but decreased specificity and limited incremental clinical benefit; negative predictive values in lesion assessment ranged from 83% to 94%, which is insufficient to replace biopsy or reliably change management. Decisions to use radiopharmaceutical-based breast imaging must also weigh the potential benefit against additional radiation exposure.
Procedure code S8080 is explicitly listed in the policy as investigational and not covered. Claims submitted using S8080 are subject to denial consistent with the investigational coverage stance.
The policy does not enumerate additional program-specific exclusions in these sections. Where applicable, providers should refer to Medicare LCDs/NCDs for any additional covered diagnoses or restrictions that may supersede or clarify coverage for Medicare beneficiaries.
Based on review of diagnostic accuracy studies, meta-analyses, and guideline information, scintimammography, BSGI, and MBI are considered investigational (not covered) for all intended clinical applications because the evidence does not demonstrate consistent improvement in net health outcomes compared with standard diagnostic or surgical management.
Specifically, the policy cites insufficient evidence to support many diagnostic and surgical-planning applications (e.g., replacing biopsy, substituting for MRI for preoperative planning, or replacing standard axillary staging) and therefore does not authorize these uses as medically necessary.
Several diagnostic and surgical-planning indications have been evaluated but remain unsupported: assessment of indeterminate or suspicious lesions (NPV reported 83%–94% and not adequate to defer biopsy), detection of residual tumor after neoadjuvant therapy (pooled sensitivity 86% and specificity 69% but no demonstrated clinical utility), and preoperative disease detection for surgical planning where comparative data show MRI may identify more patients unsuitable for breast-conserving therapy than BSGI. For these uses, the evidence is insufficient to conclude improved clinical outcomes, and they are considered investigational.
Policy history includes multiple consensus reviews and administrative updates. Prior entries note periodic literature and coding reviews, editorial updates, and statements that policy conclusions have remained unchanged through successive reviews. See the policy history for dates of consensus reviews, administrative updates, and coding changes.
Covered Indications
inv-38: Sentinel lymph node localization for breast cancer surgical staging
Considered medically necessary
inv-39: Adjunct imaging for inconclusive mammography (investigational)
Adjunct tests must demonstrate high NPV to preclude biopsy; evidence insufficient
inv-40: Adjunct to mammography in dense breasts or high-risk patients
Sensitivity increased while specificity decreased in studies
inv-41: Sentinel lymph node localization during breast cancer surgery
Considered medically necessary for SLN localization
inv-42: Scintimammography or gamma imaging for breast and axilla when a listed malignant breast neoplasm diagnosis (ICD-10 C50.*) is present.
Document the specific C50.* code when submitting claims
Coding
| Tc-99m sestamibi | Primary radiopharmaceutical used with BSGI/MBI (drug/radionuclide) |
| Tc-99m tetrofosmin | Gamma-emitter used in some BSGI studies; FDA-approved for cardiac imaging only |
| Tc-99m pertechnetate-labeled colloids | Radiopharmaceuticals used for lymphoscintigraphy |
| Tc-99m tilmanocept (Lymphoseek) | Radiopharmaceutical approved for lymph node localization in breast cancer |
| Tc-99m sulfur colloid | Historically used for intraoperative sentinel node localization |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right female breast. |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left female breast. |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified female breast. |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast. |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast. |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast. |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast. |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast. |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast. |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast. |
Provider Actions and Documentation
Product-specific prior authorization may apply
This policy applies only to certain Capital BlueCross programs and products; benefit variations may affect whether prior authorization is required for an individual member's services.
- Verify applicable product and benefit plan before scheduling or billing.
Prior authorization / medical necessity for listed codes
Services listed as "Covered when medically necessary" (examples: 78800, 78801, 78835, A9500, A9520, A9541) require documentation of medical necessity per the member's benefit terms and may require prior authorization according to plan rules.
- Provide clinical documentation that supports medical necessity when submitting requests or claims.
- Confirm prior authorization requirements with the member's plan.
Prior authorization — diagnosis-based coverage
Coverage for scintimammography or gamma imaging of the breast/axilla is diagnosis-driven; medical necessity is supported only when the claim is associated with one of the listed ICD-10-CM C50.* malignant breast neoplasm diagnosis codes.
- Ensure the submitted diagnosis is one of the C50.* codes listed in the policy to support coverage determination.
Provider: verify benefits and document medical necessity
Verify member benefits and document medical necessity prior to performing or billing for imaging; coding lists in the policy do not guarantee coverage.
- Check member's plan for coverage and reimbursement rules.
- Obtain prior authorization if required by the member's product.
Confirm plan-specific authorization rules
Confirm plan-specific prior authorization and benefit rules before ordering investigational or specialized breast imaging procedures.
- Do not rely on code lists alone to determine eligibility; consult member benefit details.
Include relevant clinical and imaging documentation
When submitting requests, include clinical indications, prior imaging results, and any relevant pathology or surgical plans to support medical necessity determinations.
- Attach mammography/ultrasound reports and biopsy/pathology reports when applicable.
Document clinical indication for sentinel lymph node localization
Documentation supporting sentinel lymph node localization (lymphoscintigraphy/hand‑held gamma detection) should align with clinical indications for sentinel lymph node biopsy as an alternative to full axillary dissection (e.g., clinically invasive breast cancer being surgically staged).
- Include indication that the procedure is for SLN identification for surgical staging.
- Provide operative plan indicating intended use of SLN biopsy instead of full axillary dissection.
Coverage subject to member benefits and medical necessity
Coverage and claim decisions are subject to the member's benefit information and medical necessity determination; presence of a listed code does not guarantee payment.
- Verify member eligibility and benefit limitations prior to service.
- Medical necessity and coverage are determined case-by-case per plan.
Document specific C50.* diagnosis code
Document the specific ICD-10-CM C50.* diagnosis code that corresponds to the member's breast malignancy when submitting requests or claims to support medical necessity for scintimammography or gamma imaging.
- Include the exact C50.* code (e.g., C50.411) that matches the clinical site of disease.
Investigational procedures are at risk of denial
Requests for scintimammography, BSGI, or MBI are at risk of denial because these procedures are considered investigational for all applications per the policy.
- Expect denials for diagnostic or screening uses of scintimammography/BSGI/MBI unless policy-listed exceptions apply (e.g., not applicable for investigational stance).
Diagnosis code mismatch may lead to denial
Claims for scintimammography or gamma imaging may be denied if the submitted diagnosis code is not one of the C50.* malignant neoplasm codes listed as covered when medically necessary.
- Confirm the diagnosis code on the claim matches a listed C50.* code to support coverage.
Definitions
Contrast / Radiopharmaceutical Rules
Radiopharmaceuticals — primary agents noted
No contrast agent rules are specified for these imaging procedures; primary agents referenced are radiopharmaceuticals such as Tc-99m sestamibi for BSGI/MBI and Tc-99m colloids/tilmanocept for lymphoscintigraphy.
- Do not report iodinated or MRI contrast rules—use nuclear medicine radiopharmaceutical supplies and billing conventions.
Tc-99m sestamibi labeled as second-line after mammography
Tc-99m sestamibi is FDA-labeled for breast imaging as a second-line diagnostic drug after mammography to assist evaluation of breast lesions and is not indicated for screening or to confirm presence/absence of malignancy.
- When using Tc-99m sestamibi, document that it is being used as a second-line diagnostic adjunct after mammography for an abnormal mammogram or palpable mass.
Not Covered
All applications of scintimammography, BSGI, and MBI — including use as an adjunct to mammography, for axillary staging, or for other diagnostic or surgical-planning purposes — are considered investigational and are not covered because available evidence does not demonstrate improved net health outcomes when compared with current standards of care.
Use of scintimammography, BSGI, or MBI as a screening test for breast cancer is not supported by product labeling or the evidence base and is therefore not covered. Tc-99m sestamibi labeling expressly states it is not indicated for screening and is intended as a second-line diagnostic adjunct after mammography.
Prior Authorization
Confirm product applicability and prior authorization
Policy applicability and prior authorization rules may vary by product; confirm applicability for the member's specific Capital BlueCross program before ordering any listed modality.
- Contact plan-specific utilization management to determine prior authorization requirements.
BSGI/MBI and radiopharmaceutical procedures — document medical necessity and check prior auth
For BSGI/MBI and radiopharmaceutical-based procedures listed as 'Covered when medically necessary' (e.g., CPT/HCPCS codes 78800, 78801, 78835, A9500, A9520, A9541), submit medical necessity documentation per member benefit; prior authorization may be required by plan.
- Provide supporting clinical records and diagnosis codes when requesting authorization.
- Verify whether the member's plan requires prior authorization for these codes.
Background
Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) are nuclear medicine techniques that use injected radiopharmaceuticals and gamma camera technology to image breast tissue. The most commonly used agent for BSGI/MBI is Tc-99m sestamibi. BSGI/MBI systems use specialized gamma cameras — including single- or dual-head detectors or dedicated breast cameras positioned close to the compressed breast — to improve spatial resolution compared with conventional planar scintimammography. These modalities were developed to enhance tumor detection in select clinical situations but carry additional radiation exposure that must be considered when weighing potential benefits against harms.
Revision History
Removed Benefit Variations section.
Added new ICD-10 codes effective 2025-10-01.
Consensus review with no change to policy statement; codes 78830, 78831, and 78832 were removed.
Consensus review with minor editorial updates to the medically necessary statement, removal of NCCN language, and reference updates; coding reviewed with no changes.
Administrative update adding clinical benefit.
Consensus review adding 'breast specific' to gamma detection statement per BCBSA and updating references; no change in intent or coding.
Consensus review adding NCCN statement and updating FEP, regulatory status, rationale, and references; no coding changes.
Consensus review with no change to policy statement.
Administrative update adding new 2020 CPT codes (78830, 78831, 78832, and 78835).
Consensus review with no changes to policy statements; coding and complete literature review performed.
Administrative update: coding reviewed and updated.
Consensus review; policy statements unchanged.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.